President and Chief Executive Officer · INOVIO PHARMACEUTICALS, INC. (INO)

J Kim

A named executive officer of INOVIO PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$6,223,600

Salary $844,056Stock awards $2,289,930

FY2020: $4,707,676

1st of 4 named executive officers at Inovio Pharmaceuticals by FY2021 total.

4 named officers on file for INOVIO PHARMACEUTICALS, FY2021

J Kim’s pay file — $29

  • 6 fiscal years of pay, line by line
  • INO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how INOVIO PHARMACEUTICALS’s whole pay program stands against its peers

  • INOVIO PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on INO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 25, 2022 (DEF 14A).

Free

Get J Kim’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

J Kim compensation by year

INOVIO PHARMACEUTICALS Summary Compensation Table · all 6 fiscal years held
In US dollars, as INOVIO PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021
Salary$643,579$780,007$726,798$837,735$694,645$844,056
Bonus$0$0$0$0$0$0
Stock awards$1,207,440$3,051,725$1,545,687$638,274$3,499,999$2,289,930
Option awards$741,099$188,818$391,922$642,803$0$2,625,258
Non-equity incentive$371,566$353,600$407,386$457,222$500,032$451,356
Pension and deferred compensation$0$0$0$0$0$0
All other$9,921$15,118$9,250$12,500$13,000$13,000
Total$2,973,605$4,389,268$3,081,043$2,588,534$4,707,676$6,223,600

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INOVIO PHARMACEUTICALS, INC. DEF 14A filed March 25, 2022, accession 0001055726-22-000030, and prior-year filings. Open the filing on EDGAR.

How this page was built: the INOVIO PHARMACEUTICALS, INC. filed document, accession 0001055726-22-000030. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2022.

$3.0M
$4.4M
$3.1M
$2.6M
$4.7M
$6.2M
FY16
FY17
FY18
FY19
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
PSU290,216$1,448,178—
RSU278,773$1,391,077—
RSU206,300$1,029,437—
RSU63,700$317,863—
Option239,850—$11.10
Option74,525—$3.34

Per the Outstanding Equity Awards at Fiscal Year-End table in INOVIO PHARMACEUTICALS, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

INOVIO PHARMACEUTICALS’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
J Kim · this pagePresident and Chief Executive Officer$6,223,600
Jacqueline SheaChief Operating Officer (7)$2,310,157
Peter KiesChief Financial Officer$2,297,817
Laurent HumeauChief Scientific Officer (6)$2,283,569

The full INOVIO PHARMACEUTICALS compensation record

free company brief

This page is one person within INOVIO PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the INOVIO PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INOVIO PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

J Kim's compensation dossier · One-time report. No refunds.